Francesco Feoli

Francesco Feoli

Auto-generated profile, based on publicly available information

Francesco Feoli

Unité d’Histopathologie et de Mycologie Cutanée, CHU Saint Pierre, ULB, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2016 in Sexually Transmitted Infections
Verified
Journal Article
Closed access
PDF file
ALAgnès Libois
Agnès Libois
FFFrancesco Feoli
Francesco Feoli
MNMarcel Nkuize
Marcel Nkuize
MDMarc Delforge
Marc Delforge
DKDeborah Konopnicki
Deborah Konopnicki
SWStéphane De Wit
Stéphane De Wit
Objective HIV-positive men who have sex with men (MSM) are at increased risk of anal cancer. We evaluate the risk factors for anal high-grade squamous intraepithelial lesion (HSIL) (the precursor of anal cancer) in HIV-positive MSM. Methods In this cross-sectional study within a cohort, 320 HIV-positive MSM were screened by anal cytology followed by high-resolution anoscopy (HRA) in case of abnormal cytology. Risk factors for anal HSIL were analysed. Results Men were mostly middle-aged Caucasians with median CD4+ T lymphocytes of 638 cells/µL, 87% on combined antiretroviral therapy (cART) for a median of 5 years. 198 anal cytology samples were normal. In the 122 patients with abnormal cytology, HRA with biopsies were performed: 12% (n=15) normal, 36% (n=44) anal low-grade squamous intraepithelial lesion (LSIL) and 51% (n=63) anal HSIL. Comparing patients with or without anal HSIL (normal cytology or normal biopsy or LSIL), we found in multivariate analysis significantly fewer anal HSIL in patients with cART ≥24 months (OR 0.32 CI 95% 0.162 to 0.631, p=0.001). Conclusions Prolonged cART (≥24 months) is associated with fewer anal HSIL.

4 July 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
YMYora Mostmans
Yora Mostmans
KSKatleen De Smedt
Katleen De Smedt
FFFrancesco Feoli
Francesco Feoli
WWWim Waelput
Wim Waelput
VMViviane de maertelaer
Viviane de maertelaer
BRBertrand JS Richert
Bertrand JS Richert
Background: Tissue expression of endothelial cell markers of microcirculatory changes in chronic spontaneous urticaria (CSU) is poorly understood. Objectives: To explore the expression of specific endothelial cell markers [stem cell factor (SCF), vascular endothelial growth factor (VEGF) and membrane attack complex (MAC)] in lesional and nonlesional CSU skin through immunohistochemistry (IHC) and in serum. Methods: Lesional and nonlesional skin biopsies from patients with CSU (n = 23) and healthy controls (n = 9) were studied by IHC for expression of SCF, VEGF and MAC. In this population, we also investigated blood levels of VEGF and SCF. Patients were also assessed for clinical characteristics, disease activity and markers of autoimmune CSU. The study was registered at ClinicalTrials.gov (NCT03443362). Results: Epidermal SCF reactivity was significantly higher in CSU lesional skin than in healthy skin (P = 0.026). In the dermis, SCF immunoreactivity was seen particularly in endothelial, perivascular and epithelial cells. In CSU lesional skin, the mean perivascular SCF staining was significantly more intense than in healthy controls (P < 0.001). Furthermore, CSU nonlesional skin also showed significantly higher SCF staining in dermal perivascular cells than in healthy controls (P < 0.001). Patients with CSU had the highest SCF immunoreactivity scores in the epidermis and/or on dermal endothelial cells. These patients did not have significantly higher SCF serum levels. Conclusions: To our knowledge, this is the first study to show elevated cutaneous expression of SCF in CSU. These findings underline the potential therapeutic possibilities of anti-Kit antibodies in CSU treatment.

11 July 2023 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
FFFrancesco Feoli
Francesco Feoli
DSDaniel Stieber
Daniel Stieber
ABAnne Bb Bormans
Anne Bb Bormans
MCMarcus Corsten
Marcus Corsten
Melanocytic matricoma is a rare benign pilar tumor characterized by matrical differentiation and interspersed dendritic melanocytes. It may show cellular atypia and brisk mitotic activity. Histological characterization of some lesions may be difficult. In addition, because the reported cases are few and have limited follow-up, there is insufficient experience to define outcome-based criteria for malignancy. Some cases of melanocytic matricoma with more prominent atypia have been reported as malignant, but their clinical behavior is uncertain. We present a melanocytic matricoma with interspersed benign dendritic melanocytes, but moderate basaloid atypia, focally brisk mitotic activity, and atypical mitoses. Despite the apparently good delimitation of this tumor, higher magnification revealed a slightly irregular border. However, overt malignant features such as necrosis, frank asymmetry, deep infiltration, and ulceration were not present. This tumor showed a complex aberrant genomic profile with multiple whole chromosomes or chromosomal arms, losses, and duplications. The tumor mutational burden was high. A loss-of-function alteration in CDKN2A and a loss-of-function mutation in TP53 were also present. This unexpected molecular profile contrasts with the relatively bland histology of the tumor and is in line with the difficulties in microscopic differential diagnosis between melanocytic matricoma and an indolent malignant pilomatrical tumor. We suggest that molecular studies and longer follow-up periods may help to further understand and more precisely categorize borderline pilomatrical tumors with melanocytic hyperplasia.

25 February 2025 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
SRShira Ronen
Shira Ronen
DSDaniel Stieber
Daniel Stieber
MFMary Ferrier
Mary Ferrier
ANAdrián Nogales-Moro
Adrián Nogales-Moro
IPIgnacio Pinilla-Pagnon
Ignacio Pinilla-Pagnon
FFFrancesco Feoli
Francesco Feoli
Pilomatrical tumors include pilomatricoma, melanocytic matricoma, and pilomatrical carcinoma. Similar to the normal anagen hair follicle bulb, they may be associated with benign and, rarely, with atypical pigmented dendritic melanocytes. It has been recently suggested that the term “melanocytic matricoma” be replaced with “pilomatricoma with melanocytic hyperplasia” (PMMH). Occasional cases of PMMH show intermediate grades of histological atypia. Their clinical behavior is uncertain. Interestingly, we found in one of these atypical tumors a molecular characterization compatible with a malignant profile. In this study, we compare this case with the molecular profiles of two PMMHs, one atypical PMMH, whose histology was previously published, and of two unpublished cases: a pilomatrical carcinoma and a large matrical tumor of difficult categorization. We also correlate histology with the molecular results. Although histologically the six cases form a morphological continuum with increasing grades of architectural and cytological atypia, our molecular analysis distinctly segregates the lesions into two molecular groups. The first group exhibits only isolated alterations in CTNNB1, a low tumor mutational burden, and a relatively stable chromosomal profile. The second group, by contrast, demonstrates mutations of TP53, biallelic inactivation of CDKN2A or RB1, and an elevated tumor mutational burden, in addition to mutations in CTNNB1 or loss of APC. The tumors in the second group are clearly different from the benign PMMHs. Atypical PMMHs could represent an early stage in the development of tumors that, since their beginning, have a malignant molecular profile different from that of PMMHs and can progressively drive their evolution toward overt malignancy.